mAb Industry in China: Biosimilars vs. Innovative Biologics

Presented by Dr Joe X Zhou, CEO at Genor Biopharma, Walvax Bio Group Following patent cliffs for Erbitux, Rituxan, Sandosta_n and several big blockbusters, Herceptin, Avastin are now among the next biosimilar targets. This is creating huge potential for biosimilars, prompting innovators to shift their focus to target more emerging markets which remain untapped for many companies. In this presentation, Joe will be sharing with you his vision of the biosimilars market with a focus on China. He will also discuss key considerations for mAb and biologics therapeutic development, providing a broad overview of challenges and opportunities presenting in the market.   1.        Landscape changes of mAb therapeutics 2.        New targets and process/manufacturing innovation 3.        Key consideration of mAb industry in China 4.        Case study: Development strategies of PD-1 mAb as anti-tumor therapeutics in China for global market Followed by Biosimilar development—how to deal with the similarity challenge Presented by Sarah (Xuyu) Wang, Head of Segment Marketing, Biosimilars and Bioconjugations at Sartorius Stedim Biotech Globally we have more than 1000 biosimilars in the pipeline till the beginning of 2019, Sales of mAb biosimilars is also taking up as popular targets being approved both in Europe and US. With the 3rd wave of the biosimilar coming the challenges is still ahead---how to keep the similarity from the beginning of the development to the manufacturing stage and cover the whole lifecycle? With the evolving cell line development platform, good analytical strategy and QbD implementation better similarity will be achieved step by step.